This preview shows pages 1–2. Sign up to view the full content.
This preview has intentionally blurred sections. Sign up to view the full version.View Full Document
Unformatted text preview: Pharmacologic Agents in the Management of Type I I Diabetes Mellitus, an Introduction D rug Class MOA Clinical Effect* Patient Education BIGUANIDES (Metformin) Decrease hepatic glucose output and sensitizes peripheral tissue to insulin A1C 1.5-2% FPG 50-70 mg/dL GI SEs (N/V/D, anorexia, metallic taste) take with food to minimize GI SEs Rare Lactic Acidosis risk SULFONYLUR EAS (Glipizide, Glimepiride, Glyburide) Insulin secretagogue (stimulate pancreatic insulin secretion) A1C 1-2 % FPG 50-70 mg/dL PPG 48 mg/dL Hypoglycemia risk Weight gain Sun sensitivity (sunscreen!) THIAZOLIDIN E-DIONES (Pioglitazon e) PPAR gamma agonist, decreases hepatic glucose output and sensitizes peripheral tissue to insulin A1C 0.5-1.4% FPG 40-55 mg/dL Weight gain Increased ovulation (females) Hepatotoxicity (jaundice) Osteoporosis risk (take calcium) Cardiac risk? (MI) NON- SULFONYLUR EA SECRETAGOG UES (Repaglinide , Nateglinide) Insulin secretagogue (stimulate pancreatic...
View Full Document
This note was uploaded on 09/14/2011 for the course PHARM TBL taught by Professor Staff during the Spring '11 term at UCSD.
- Spring '11